

Balaxi Pharmaceuticals Limited

Date: 09th May, 2026

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Intimation of Board Meeting

Dear Sir / Madam,

We wish to inform you that pursuant to Regulation 29 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 28th May, 2026, inter alia, to consider and approve the audited standalone and consolidated financial results of the Company for the fourth quarter and financial year ended 31st March, 2026.

Further, pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and the Company's Code of Conduct to regulate, monitor and report trading in securities of the Company by Designated Persons, the trading window for dealing in the securities of the Company has been closed from Wednesday, 01st April, 2026, until the expiry of 48 hours after the declaration of the audited standalone and consolidated financial results of the Company for the fourth quarter and financial year ended 31st March, 2026.

The aforesaid information will also be available on the Company's website at www.balaxipharma.in

This is for your information and record.

Thanking You.

Yours faithfully,
For Balaxi Pharmaceuticals Limited

Aman Purohit
(Company Secretary & Compliance Officer)
ICSI Membership No.: A59345

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096
CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in